Thermo Fisher Scientific Inc
Description
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
About
CEO
Mr. Marc N. Casper
Employees
122,000
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNYS
Address
168 Third Avenue, Waltham, MA 02451, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 21, 2025 | — | — | — | — |
| Jul 22, 2025 | — | — | — | — |
| Apr 22, 2025 | — | — | — | — |
| Jan 31, 2025 | 5.94 | — | — | — |
| Oct 23, 2024 | 5.25 | 5.28 | 0.03 | 0.57% |
Earnings estimate
|
Current Quarter
(Mar 2025)
|
Next Quarter
(Jun 2025)
|
Current Year
(Dec 2025)
|
Next Year
(Dec 2026)
|
|
|---|---|---|---|---|
| Number of analysts | 21 | 21 | 25 | 27 |
| Average estimate | 5.12 | 5.59 | 23.32 | 25.89 |
| Low estimate | 5.05 | 5.24 | 23.01 | 24.98 |
| High estimate | 5.29 | 5.74 | 24.14 | 27.80 |
| Last year EPS | 5.11 | 5.37 | 21.86 | 23.32 |
[stock_revenue_estimate]
Growth estimates
Current qtr (Mar 2025)
0.260%
Next qtr. (Jun 2025)
4.090%
Current year (Dec 2025)
6.660%
Next year (Dec 2026)
10.890%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B |
| Cost of revenue | 25.76B | 25.94B | 19.57B | 16.21B | 14.21B |
| Gross profit | 17.10B | 18.97B | 19.64B | 16.00B | 11.33B |
| Operating expense | |||||
| Research & development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B |
| Selling general and admin | 8.45B | 8.99B | 8.01B | 6.93B | 6.14B |
| Other operating expenses | — | — | — | — | — |
| Operating income | 7.32B | 8.51B | 10.23B | 7.89B | 4.18B |
| Non operating interest income | |||||
| Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M |
| Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M |
| Other income expense | -524.00M | -218.00M | -891.00M | -175.00M | 343.00M |
| Pretax income | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B |
| Tax provision | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M |
| Net income | 5.96B | 6.96B | 7.73B | 6.38B | 3.70B |
| Basic EPS | 15.52 | 17.75 | 19.62 | 16.09 | 9.24 |
| Diluted EPS | 15.45 | 17.63 | 19.46 | 15.96 | 9.17 |
| Basic average shares | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M |
| Diluted average shares | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M |
| EBITDA | 11.54B | 12.06B | 12.17B | 10.21B | 6.61B |
| Net income from continuing op. | 5.96B | 6.96B | 7.73B | 6.38B | 3.70B |
| Minority interests | 40.00M | -10.00M | -3.00M | -2.00M | -2.00M |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 98.73B | 97.15B | 95.12B | 69.05B | 58.38B |
| Current assets | |||||
| Cash | — | — | — | — | 1.12B |
| Cash equivalents | — | — | — | — | 1.28B |
| Cash and cash equivalents | 8.08B | 8.52B | 4.48B | 10.33B | 2.40B |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 8.22B | 8.12B | 7.98B | 5.74B | 4.35B |
| Other receivables | 1.44B | 1.31B | 968.00M | 731.00M | 603.00M |
| Inventory | 5.09B | 5.63B | 5.05B | 4.03B | 3.37B |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | — | 12.00M | 13.00M | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 1.76B | 1.64B | 1.63B | 1.13B | 1.17B |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | 458.00M | 454.00M | 431.00M | 410.00M | 396.00M |
| Machinery furniture equipment | 9.24B | 7.97B | 7.02B | 6.98B | 5.50B |
| Construction in progress | 2.24B | 2.70B | 2.57B | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -6.08B | -4.99B | -4.26B | -3.67B | -3.02B |
| Goodwill | 104.71B | 99.83B | 103.96B | 64.77B | 65.44B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 16.67B | 17.44B | 20.11B | 12.69B | 14.01B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 4.00B | 4.01B | 4.64B | 2.46B | 2.01B |
| Total liabilities | 51.88B | 53.01B | 54.15B | 34.54B | 28.71B |
| Current liabilities | |||||
| Accounts payable | 2.87B | 3.38B | 2.87B | 2.18B | 1.92B |
| Accrued expenses | 4.84B | 5.45B | 5.38B | 4.23B | 2.69B |
| Short term debt | 3.61B | 5.58B | 2.54B | 2.63B | 676.00M |
| Deferred revenue | 2.69B | 2.60B | 2.66B | 1.27B | 916.00M |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 31.31B | 28.91B | 32.33B | 19.11B | 17.08B |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 1.92B | 2.85B | 3.84B | 1.79B | 2.19B |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 4.64B | 4.24B | 4.54B | 3.33B | 3.24B |
| Shareholders equity | |||||
| Common stock | 442.00M | 441.00M | 439.00M | 437.00M | 434.00M |
| Retained earnings | 47.36B | 41.91B | 35.43B | 28.12B | 22.09B |
| Other shareholders equity | -3.22B | -3.10B | -2.33B | -2.81B | -2.68B |
| Total shareholders equity | 46.84B | 44.15B | 40.98B | 34.52B | 29.68B |
| Additional paid in capital | 17.29B | 16.74B | 16.17B | 15.58B | 15.06B |
| Treasury stock | 15.13B | 12.02B | 8.92B | 6.82B | 5.24B |
| Minority interest | 107.00M | 170.00M | 184.00M | 10.00M | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||
| Net Income | 5.96B | 6.96B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.03B | 1.98B | 1.90B | 1.28B | 1.26B | 1.02B | 997.00M | 851.30M | 975.40M | 761.10M | 168.94M | 198.30M | 218.37M | 175.21M | 309.73M | -781,000 | -23.73M | -176.10M | 181.50M | 239.40M | 190.80M | 140.10M | 103.40M | 76.60M | 60.60M | 47.10M | 33.90M | 24.60M |
| Depreciation | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 859.60M | 746.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 46.72M | 56.38M | 98.52M | 97.49M | 113.60M | 96.10M | 86.10M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M |
| Deferred Taxes | -1.30B | -995.00M | -647.00M | -552.00M | -302.00M | -379.00M | -1.10B | -620.00M | -525.00M | -621.80M | -472.80M | -301.60M | -123.10M | -267.60M | -248.60M | -131.40M | -90.80M | -73.63M | -5.42M | 3.00M | -17.25M | 23.77M | -16.75M | -39.70M | -61.30M | -13.50M | 29.60M | 20.90M | 4.60M | 9.40M | 13.90M | 12.30M | 200,000 | -200,000 | -2.10M |
| Stock-Based Compensation | 278.00M | 307.00M | 230.00M | 196.00M | 181.00M | 181.00M | 159.00M | 133.00M | 125.00M | 117.10M | 90.90M | 78.20M | 80.00M | 81.80M | 68.10M | 57.10M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 562.00M | 483.00M | 156.00M | 242.00M | 32.00M | 10.00M | -14.00M | 99.00M | 23.00M | -11.60M | -15.50M | 30.50M | 24.20M | 84.20M | 90.00M | 71.10M | 55.00M | 174.49M | — | — | — | — | 34.26M | — | -100,000 | 100,000 | 100,000 | 126.30M | 103.80M | 41.40M | 58.00M | 25.50M | 19.20M | 3.90M | 3.20M |
| Accounts Receivable | 209.00M | -784.00M | 17.00M | -1.30B | -225.00M | -366.00M | -362.00M | -352.00M | -149.00M | -145.40M | -147.90M | 12.00M | -101.20M | -80.00M | 127.30M | -50.90M | -10.00M | 32.13M | -65.50M | -27.61M | 931,000 | 4.54M | -19.04M | -27.40M | -27.30M | -1.10M | -19.80M | -17.10M | -49.40M | -7.60M | -43.20M | -10.80M | -10.20M | -10.30M | -600,000 |
| Accounts Payable | -500.00M | 648.00M | 479.00M | 59.00M | 266.00M | 201.00M | 274.00M | 56.00M | -3.00M | 1.20M | 47.00M | 10.00M | 33.80M | 2.50M | -44.90M | -123.90M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -204.00M | -872.00M | -2.01B | 944.00M | -854.00M | -300.00M | 582.00M | 118.00M | -233.00M | 312.10M | 221.60M | -56.30M | -329.20M | -180.00M | 16.10M | -142.90M | -21.30M | -142.95M | 27.97M | -15.13M | 20.15M | -61.21M | 45.10M | -34.08M | 5.00M | 58.30M | -25.90M | -66.90M | -15.10M | 31.00M | 8.70M | -30.20M | -14.60M | -15.00M | 33.90M |
| Operating Cash Flow | 8.41B | 9.13B | 8.55B | 8.29B | 5.07B | 4.55B | 3.80B | 3.22B | 2.91B | 3.23B | 2.00B | 2.01B | 1.47B | 1.38B | 1.65B | 1.45B | 1.45B | 399.75M | 278.63M | 244.78M | 225.75M | 333.21M | 141.31M | -27.42M | -146.20M | 321.40M | 309.50M | 369.20M | 269.00M | 239.90M | 156.40M | 86.60M | 65.10M | 31.10M | 71.70M |
| Investing Activities | |||||||||||||||||||||||||||||||||||
| Capital Expenditures | -1.39B | -2.22B | -2.50B | -1.47B | -890.00M | -708.00M | -501.00M | -418.00M | -405.00M | -378.30M | -261.70M | -302.30M | -252.70M | -247.60M | -194.10M | -249.00M | -156.30M | -71.01M | -21.73M | -44.47M | -20.99M | -16.64M | -26.39M | 201.37M | -465.50M | -247.40M | -533.50M | -114.00M | -57.30M | -38.80M | -56.60M | -58.40M | -31.10M | -117.60M | -45.00M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -3.66B | -39.00M | -19.40B | -38.00M | -715.00M | -536.00M | -7.23B | -5.18B | -695.00M | -11.54B | -11.40M | -1.08B | -5.68B | -606.20M | -632.90M | -198.00M | -486.20M | 236.51M | -933.22M | -143.01M | -134.92M | -78.68M | -83.66M | -15.81M | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100,000 | -8.10M | -87.82M | -231.90M | -611.10M | -245.70M | -83,000 | -969.27M | -473.58M | -551.40M | -1.91B | -830.30M | -831.00M | -570.10M | -748.90M | -214.50M | — | -248.40M | -9.50M | -55.60M |
| Sale of Investments | 70.00M | 15.00M | 8.00M | — | — | — | 22.00M | 81.20M | 12.00M | 88.60M | 7.60M | 1.90M | 47.10M | 9.00M | 800,000 | 600,000 | 7.70M | 159.89M | 369.82M | 664.81M | 642.41M | 339.11M | 830.57M | 516.35M | 1.08B | 1.64B | 1.40B | — | 617.10M | 495.40M | 16.70M | 68.30M | 15.80M | 65.40M | 11.60M |
| Investing Cash Flow | -5.14B | -2.16B | -21.93B | -1.51B | -1.49B | -1.25B | -7.71B | -5.44B | -1.09B | -11.78B | -263.30M | -1.43B | -5.89B | -855.30M | -828.70M | -457.90M | -617.30M | 278.63M | -819.09M | -137.67M | 302.36M | 357.49M | -271.50M | 229.58M | 83.50M | -575.10M | 91.80M | -1.31B | -382.00M | -450.00M | -399.30M | -410.60M | -278.40M | -76.00M | -96.60M |
| Financing Activities | |||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 5.94B | 3.19B | 18.14B | 3.46B | 5.64B | 690.00M | 6.46B | 7.60B | 1.80B | 6.59B | 3.17B | 1.28B | 4.25B | 741.40M | 748.20M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -7.72B | -4.07B | -11.74B | -1.10B | -9.82B | -7.31B | -11.81B | -12.61B | -11.67B | -4.47B | -13.00M | -354.50M | -453.40M | -1.11B | -948.10M | -151.50M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | 56.00M | -9.00M | 65.00M | -150.00M | -74.00M | -51.00M | -3.00M | -14.00M | -6.00M | 57.10M | 30.90M | 18.10M | 20.80M | 12.80M | 2.60M | 25.40M | 96.80M | 17.38M | -2.02M | -548,000 | 40,000 | 2.97M | -1.76M | 13.54M | -7.30M | -23.30M | 12.70M | -1.30M | 1.10M | 300,000 | -1.00M | 134.00M | -400,000 | -800,000 | 10.00M |
| Financing Cash Flow | -5.56B | -6.50B | 6.58B | 376.00M | -6.74B | -7.63B | -4.79B | -5.61B | -10.57B | 4.64B | 3.07B | -1.17B | 3.55B | -1.30B | -578.60M | -243.80M | -455.80M | -102.29M | 25.17M | 57.09M | -13.78M | -305.85M | -443.28M | 72.00M | -182.80M | -109.20M | 20.80M | 161.80M | 76.60M | -40.60M | 320.60M | 189.40M | 52.80M | 51.00M | 24.90M |
| Other Cash Details | |||||||||||||||||||||||||||||||||||
| End Cash Position | 8.10B | 8.54B | 4.49B | 10.34B | 2.42B | 2.12B | 1.36B | 811.00M | 466.00M | 1.34B | 5.83B | 805.60M | 1.02B | 917.10M | 1.56B | 1.28B | 625.10M | 667.43M | 214.33M | 326.89M | 195.77M | 339.07M | 305.20M | 636.25M | 281.80M | 268.40M | 505.60M | — | 462.00M | 382.80M | — | — | — | — | — |
| Income Tax Paid | 1.48B | 1.23B | 2.18B | 1.32B | 896.00M | 591.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 1.39B | 667.00M | 555.00M | 471.00M | 790.00M | 687.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 6.93B | 6.91B | 6.79B | 6.82B | 4.05B | 3.79B | 3.50B | 2.81B | 2.52B | 2.19B | 1.73B | 1.72B | 1.43B | 1.24B | 1.45B | 1.16B | 1.31B | 328.86M | 227.37M | 214.53M | 173.06M | 51.68M | 103.60M | 125.88M | -460.10M | -231.90M | -755.10M | 100.00M | 131.70M | 144.00M | 70.10M | -5.10M | -10.50M | -101.40M | -300,000 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 12,106,185 | 7.03B | 3.17% |
| Vanguard 500 Index Fund | Sep 30, 2024 | 10,004,240 | 5.81B | 2.62% |
| SPDR S&P 500 ETF Trust | Nov 30, 2024 | 4,713,917 | 2.74B | 1.23% |
| Fidelity 500 Index Fund | Nov 30, 2024 | 4,720,272 | 2.74B | 1.23% |
| iShares Core S&P 500 ETF | Nov 30, 2024 | 4,317,303 | 2.51B | 1.13% |
| Growth Fund of America Inc | Nov 30, 2024 | 3,533,712 | 2.05B | 0.92% |
| Vanguard Index-Value Index Fund | Sep 30, 2024 | 3,233,342 | 1.88B | 0.85% |
| Select Sector SPDR Fund-Health Care | Nov 30, 2024 | 2,789,540 | 1.62B | 0.73% |
| Vanguard Institutional Index Fund-Institutional Index Fund | Sep 30, 2024 | 2,429,697 | 1.41B | 0.64% |
| Amcap Fund | Nov 30, 2024 | 2,380,459 | 1.38B | 0.62% |
Article
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.
Feb 5, 2025
Article
Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 10-year virtual power purchasing agreement (VPPA) with international renewable energy developer X-ELIO designed to increase access to renewable electricity across the pharmaceutical and healthcare supply chains. The Lorca solar project is expected to be operational in early 2026 and includes a cohort of three partners from the pharmaceutical and healthcare sectors.
Feb 4, 2025
Article
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Jan 31, 2025
